References
- Zetterberg A, Skern T, Schoberl E, Bergman T, Jornvall H. Molecular characterization of TPS (Abstract). 22nd Meeting, ISOBM. 1994. Groningen, 354
- Björklund B, Björklund V. Antigenicity of pooled human malignant and normal tissue by cytoimmunological techniques: Presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy 1957; 10: 153–84
- Björklund B, Björklund V, Brunkener M, Grönlund H, Back M. The enigma of a human tumor marker: TPA revised. Human tumor markers, F Cimino, G D Birkmayer, J V Klavins, E Pimentel, F Salvatore. Walter de Gruyter, Berlin 1987; 169–80
- Björklund B, Björklund V. Biochemische und morphologische Grundlagen von TPA: Fortschritte in Richtung auf einem allgemein Marker fur aktive Tumoren durch monoklonale Kartierung. Tumormarkersystem CEA-TPA, M Lutgens, G Schlegel. Tumor Diagnostik-Verlag, Leonberg 1987; 14–30
- Glimelius B, Hoffman K, Einarsson R, Pahlman L, Graf W. Monätoring palliative chemotherapy in advanced gastrointestinal cancer using tissue polypeptide specific antigen (TPS) measurements. Acta Oncol 1996; 35: 141–8
- Bremer K, Eklund G, Björklund B. Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer. Anticancer Res 1996; 16: 905–9
- Mogensen O, Mogensen B, Jakobsen A. Alpha,-acid glucoprotein in ovarian cancer with a reference to immunosuppressive acidic protein and cancer antigen 125. Cancer 1989; 64: 1867–71
- Mogensen O, Mogensen B, Jakobsen A, Sell A. Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation. Eur J Cancer Clin Oncol 1988; 24: 1835–7